CERo Therapeutics announces 1-for-20 reverse stock split effective June 13, 2025

CERO THERAPEUTICS HOLDINGS, INC.

Outstanding shares reduced from ~10,321,839 to ~516,092; par value $0.0001 unchanged.
Split-adjusted trading begins June 13 under symbol CERO; new CUSIP 71902K402.
No fractional shares; fractional holders receive rounding up to next whole share.
Proportional adjustments made to outstanding options, warrants, and preferred stock.
Stockholders approved a 1-for-2 to 1-for-25 range at May 29, 2025 annual meeting; board set 1-for-20.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.95

CERO THERAPEUTICS HOLDINGS, INC.: The Company filed a Certificate of Amendment to its Second Amended and Restated Certificate of Incorporation to effect a 1-for-20 reverse stock split of its common stock, effective June 13, 2025 (effective 2025-06-13).

Change: charter amendment
Effective: 2025-06-13

Exact text from the filing

On June 11, 2025, CERo Therapeutics Holdings, Inc. (the “Company”) filed an amendment (the “Certificate of Amendment”) to its Second Amended and Restated Certificate of Incorporation, as amended and/or restated from time to time, to effectuate a reverse stock split of the Company’s issued and outstanding shares of common stock, par value $0.0001 per share (the “Common Stock”).

View on SEC.gov

89 governance changes filed in the last 30 days. Browse all governance changes →

CERO THERAPEUTICS HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001213900-25-053292

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.